Biweekly cabazitaxel is safe to treat metastatic castration-resistant prostate cancer after docetaxel therapy

A study published in the journal “Anticancer Research” stated that biweekly cabazitaxel results in clinically significant benefits and is a well-tolerated even after docetaxel for heavily pretreated metastatic castration-resistant prostate cancer (CRPC) patients.

Pirkko-Liisa Kellokumpu-Lehtinen et al. undertook this study (Final Analysis of the Prosty II Trial) to explore the safety of a biweekly treatment schedule with cabazitaxel among metastatic CRPC patients post-docetaxel therapy.

Overall, 60 patients (mean age 67 years) were administered with cabazitaxel 16 mg/m2 intravenously on days 1 and 14 of a four-week cycle. The mean serum prostate-specific antigen (PSA) levels were 305 ng/ml. The primary outcome parameter was safety according to Common Terminology Criteria for Adverse Events (CTCAE). The secondary outcome parameters were improvement in the quality of life, time to therapy failure, response, survival.

Notably, 255 four-week cycles of cabazitaxel were given. Pain (13.3%), neutropenia (16.7%), anemia (5 %), fatigue (10 %), and non-neutropenic infection (10 %) were the most common grade 3/4 adverse events. In 16.7% (n=10) patients, the PSA responses occurred. The median survival was found to be ten months, and the clinical benefit rate was 38.3%.

Thus, biweekly cabazitaxel is a safe therapeutic choice to treat metastatic CRPC patients after docetaxel therapy.

Also, get knowledge about ‘Novel Guidelines for Treating Advanced Prostate Cancer‘.